Abstract:Background: The generation of liver organoids recapitulating parenchymal and non-parenchymal cell interplay is essential for the precise in vitro modeling of liver diseases. Although different types of multilineage liver organoids (mLOs) have been generated from human pluripotent stem cells (hPSCs), the assembly and concurrent differentiation of multiple cell types in individual mLOs remain a major challenge. Particularly, most studies focused on the vascularization of mLOs in host tissue after transplantation in vivo. However, relatively little information is available on the in vitro formation of luminal vasculature in mLOs themselves. Methods: The mLOs with luminal blood vessels and bile ducts were generated by assembling hepatic endoderm, hepatic stellate cell-like cells (HscLCs), and endothelial cells derived entirely from hPSCs using 96-well ultra-low attachment plates. We analyzed the effect of HscLC incorporation and Notch signaling modulation on the formation of both bile ducts and vasculature in mLOs using immunofluorescence staining, qRT-PCR, ELISA, and live-perfusion imaging. The potential use of the mLOs in fibrosis modeling was evaluated by histological and gene expression analyses after treatment with pro-fibrotic cytokines. Results: We found that hPSC-derived HscLCs are crucial for generating functional microvasculature in mLOs. HscLC incorporation and subsequent vascularization substantially reduced apoptotic cell death and promoted the survival and growth of mLOs with microvessels. In particular, precise modulation of Notch signaling during a specific time window in organoid differentiation was critical for generating both bile ducts and vasculature. Live-cell imaging, a series of confocal scans, and electron microscopy demonstrated that blood vessels were well distributed inside mLOs and had perfusable lumens in vitro. In addition, exposure of mLOs to pro-fibrotic cytokines induced early fibrosis-associated events, including upregulation of genes associated with fibrotic induction and endothelial cell activation (i.e., collagen I, α-SMA, and ICAM) together with destruction of tissue architecture and organoid shrinkage. Conclusion: Our results demonstrate that mLOs can reproduce parenchymal and non-parenchymal cell interactions and suggest that their application can advance the precise modeling of liver diseases in vitro.

Generation of in vivo -like multicellular liver organoids by mimicking developmental processes: A review

Human liver organoids: From generation to applications

Generation of Multicellular 3D Liver Organoids From Induced Pluripotent Stem Cells as a Tool for Modelling Liver Diseases

Liver organoids: updates on generation strategies and biomedical applications

Liver Organoids: Established Tools for Disease Modeling and Drug Development

The liver organoid's past, present and future: a personalized medicine strategy

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Progress, Application and Challenges of Liver Organoids

Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet?

Induced Pluripotent Stem Cells (Ipscs) Based Liver Organoid: the Benefits and Challenges

Using Liver Organoids as Models to Study the Pathobiology of Rare Liver Diseases

Generation of multilineage liver organoids with luminal vasculature and bile ducts from human pluripotent stem cells via modulation of Notch signaling

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment

Liver Organoids, Novel and Promising Modalities for Exploring and Repairing Liver Injury

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Liver Organoid Research: Present Situation, limiting Factors and Future Therapeutical Potential in Pediatric Diseases

Advances and Applications in Liver Organoid Technology

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine